These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 27201926

  • 21. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
    Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, Baladi JF, Habr D, Kriemler-Krahn U, El-Beshlawy A.
    Acta Haematol; 2010; 123(4):220-5. PubMed ID: 20424435
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
    Origa R, Danjou F, Cossa S, Matta G, Bina P, Dessì C, Defraia E, Foschini ML, Leoni G, Morittu M, Galanello R.
    Br J Haematol; 2013 Nov; 163(3):400-3. PubMed ID: 24033185
    [Abstract] [Full Text] [Related]

  • 24. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Nov; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 25. Overview of iron chelation therapy with desferrioxamine and deferiprone.
    Cappellini MD, Musallam KM, Taher AT.
    Hemoglobin; 2009 Nov; 33 Suppl 1():S58-69. PubMed ID: 20001633
    [Abstract] [Full Text] [Related]

  • 26. Recent advances in improving the management of sickle cell disease.
    Inati A.
    Blood Rev; 2009 Dec; 23 Suppl 1():S9-13. PubMed ID: 20116638
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The effects of physician empathy on patient satisfaction and compliance.
    Kim SS, Kaplowitz S, Johnston MV.
    Eval Health Prof; 2004 Sep; 27(3):237-51. PubMed ID: 15312283
    [Abstract] [Full Text] [Related]

  • 29. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
    Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Diez Campelo M, Sanz G, IRON-2 Study Group.
    Ann Hematol; 2015 May; 94(5):779-87. PubMed ID: 25516455
    [Abstract] [Full Text] [Related]

  • 30. The relation of patient satisfaction with treatment of otitis externa to clinical outcomes: development of an instrument.
    Shikiar R, Halpern MT, McGann M, Palmer CS, Seidlin M.
    Clin Ther; 1999 Jun; 21(6):1091-104. PubMed ID: 10440629
    [Abstract] [Full Text] [Related]

  • 31. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Jun; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 32. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF.
    Acta Haematol; 2008 Jun; 119(3):133-41. PubMed ID: 18408362
    [Abstract] [Full Text] [Related]

  • 33. Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy.
    Sheth S, Ruzal-Shapiro C, Hurlet-Jensen A, Piomelli S, Berdon WE.
    Pediatr Radiol; 1997 Dec; 27(12):926-8. PubMed ID: 9388284
    [Abstract] [Full Text] [Related]

  • 34. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM, Koren G.
    Bone Marrow Transplant; 1993 Dec; 12 Suppl 1():9-11. PubMed ID: 8374574
    [Abstract] [Full Text] [Related]

  • 35. Oral iron chelators.
    Kwiatkowski JL.
    Pediatr Clin North Am; 2008 Apr; 55(2):461-82, x. PubMed ID: 18381096
    [Abstract] [Full Text] [Related]

  • 36. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.
    Porter JB, Davis BA.
    Best Pract Res Clin Haematol; 2002 Jun; 15(2):329-68. PubMed ID: 12401311
    [Abstract] [Full Text] [Related]

  • 37. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Jun; 33(5):283-6. PubMed ID: 19814673
    [Abstract] [Full Text] [Related]

  • 38. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
    Van de Vijver E, Desager K, Mulberg AE, Staelens S, Verkade HJ, Bodewes FA, Malfroot A, Hauser B, Sinaasappel M, Van Biervliet S, Behm M, Pelckmans P, Callens D, Veereman-Wauters G.
    J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
    [Abstract] [Full Text] [Related]

  • 39. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.
    Oliva EN, Ronco F, Marino A, Alati C, Praticò G, Nobile F.
    Transfusion; 2010 Jul; 50(7):1568-70. PubMed ID: 20230535
    [Abstract] [Full Text] [Related]

  • 40. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.